Genmab Adr (GMAB)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Perché GMAB Giù? Forum Previsione Frazionamento azionario

Perché le azioni Genmab Adr (GMAB) sono in ribasso?

Abbiamo notato un calo di 6.29% nelle azioni di Genmab Adr (GMAB) durante la sessione di negoziazione di 2026-06-02. Sebbene ciò possa essere attribuito alla normale volatilità o a vari fattori interni ed esterni, tieni presente che stiamo monitorando attivamente la situazione e forniremo aggiornamenti tempestivi il prima possibile!

2023-10-18:

Genmab A/S Stock (GMAB) dropped by 7.96% from $31.92 to $29.38 in the trading on Wednesday October 18, 2023. The reasons why GMAB stock down today include:

Key drug Darzalex Q3 sales: Danish biotech reported that Darzalex, a multiple myeloma therapy the company markets with Johnson & Johnson (JNJ), generated $2.5B in net sales in Q3 2023, 2% less than what was expected by both companies.
Concerns about Epkinly launch: Epkinly, Genmab's newly FDA-approved lymphoma drug, is navigating a competitive landscape with peer Roche's Columvi, impacting its market reception and potential earnings.
Rating from analyst: Nordnet analyst Per Hansen flags Exane BNP Paribas' initiation of coverage with an 'underperform' rating due to Epkinly concerns, which is a headwind causing GMAB stock down today.

MRNA

$64.45

2.20%

ROIV

$36.23

0.07%

RPRX

$59.46

1.21%

INSM

$128.31

3.20%

ALNY

$224.60

1.62%

ONC

$362.66

4.27%

Genmab Adr (GMAB)

Perché le azioni Genmab Adr (GMAB) sono in ribasso?

Simile a GMAB